These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 2557169)

  • 1. Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution.
    Lind MJ; Margison JM; Cerny T; Thatcher N; Wilkinson PM
    Cancer Chemother Pharmacol; 1989; 25(2):139-42. PubMed ID: 2557169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theophylline disposition in obesity.
    Gal P; Jusko WJ; Yurchak AM; Franklin BA
    Clin Pharmacol Ther; 1978 Apr; 23(4):438-44. PubMed ID: 630791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cimetidine disposition in obesity.
    Abernethy DR; Greenblatt DJ; Matlis R; Gugler R
    Am J Gastroenterol; 1984 Feb; 79(2):91-4. PubMed ID: 6364798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Digoxin disposition in obesity: clinical pharmacokinetic investigation.
    Abernethy DR; Greenblatt DJ; Smith TW
    Am Heart J; 1981 Oct; 102(4):740-4. PubMed ID: 7282520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obesity, sex, and acetaminophen disposition.
    Abernethy DR; Divoll M; Greenblatt DJ; Ameer B
    Clin Pharmacol Ther; 1982 Jun; 31(6):783-90. PubMed ID: 7075126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity effects on nitrazepam disposition.
    Abernethy DR; Greenblatt DJ; Locniskar A; Ochs HR; Harmatz JS; Shader RI
    Br J Clin Pharmacol; 1986 Nov; 22(5):551-7. PubMed ID: 3790401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of ifosfamide and its enantiomers following a single 1 h intravenous infusion of the racemate in patients with small cell lung carcinoma.
    Corlett SA; Parker D; Chrystyn H
    Br J Clin Pharmacol; 1995 Apr; 39(4):452-5. PubMed ID: 7640155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxorubicin clearance in the obese.
    Rodvold KA; Rushing DA; Tewksbury DA
    J Clin Oncol; 1988 Aug; 6(8):1321-7. PubMed ID: 3411343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
    Kurowski V; Wagner T
    Cancer Chemother Pharmacol; 1997; 39(5):431-9. PubMed ID: 9054957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of age on the pharmacokinetics of ifosfamide.
    Lind MJ; Margison JM; Cerny T; Thatcher N; Wilkinson PM
    Br J Clin Pharmacol; 1990 Jul; 30(1):140-3. PubMed ID: 2167716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbamazepine pharmacokinetics in obese and lean subjects.
    Caraco Y; Zylber-Katz E; Berry EM; Levy M
    Ann Pharmacother; 1995 Sep; 29(9):843-7. PubMed ID: 8547729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study.
    You B; Tranchand B; Girard P; Falandry C; Ribba B; Chabaud S; Souquet PJ; Court-Fortune I; Trillet-Lenoir V; Fournel C; Tod M; Freyer G
    Lung Cancer; 2008 Nov; 62(2):261-72. PubMed ID: 18442869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects.
    Cheymol G; Woestenborghs R; Snoeck E; Ianucci R; Le Moing JP; Naditch L; Levron JC; Poirier JM
    Eur J Clin Pharmacol; 1997; 51(6):493-8. PubMed ID: 9112066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Procainamide disposition in obesity.
    Christoff PB; Conti DR; Naylor C; Jusko WJ
    Drug Intell Clin Pharm; 1983; 17(7-8):516-22. PubMed ID: 6191939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lidocaine disposition in obesity.
    Abernethy DR; Greenblatt DJ
    Am J Cardiol; 1984 Apr; 53(8):1183-6. PubMed ID: 6702701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of cisplatin, ifosfamide with mesna, and etoposide (PIE) chemotherapy for advanced non-small cell lung cancer.
    Shirinian M; Lee JS; Dhingra HH; Greenberg J; Hong WK
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):49-53. PubMed ID: 1329212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients.
    Boddy AV; Proctor M; Simmonds D; Lind MJ; Idle JR
    Eur J Cancer; 1995; 31A(1):69-76. PubMed ID: 7695982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate).
    Abernethy DR; Greenblatt DJ; Divoll M; Shader RI
    J Pharm Sci; 1982 Aug; 71(8):942-4. PubMed ID: 6811726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caffeine disposition in obesity.
    Abernethy DR; Todd EL; Schwartz JB
    Br J Clin Pharmacol; 1985 Jul; 20(1):61-6. PubMed ID: 4027137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenytoin disposition in obesity. Determination of loading dose.
    Abernethy DR; Greenblatt DJ
    Arch Neurol; 1985 May; 42(5):468-71. PubMed ID: 3994563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.